Gene amplification in human neuroblastomas: Basic me

Cancer Genetics and Cytogenetics 19, 101-111 DOI: 10.1016/0165-4608(86)90377-8

Citation Report

#	Article	IF	CITATIONS
1	Clinical implications of oncogene activation in human neuroblastomas. Cancer, 1986, 58, 541-545.	4.1	68
2	Cytogenetic studies on human breast carcinomas. Breast Cancer Research and Treatment, 1986, 8, 125-138.	2.5	89
3	Gene Amplification of c- <i>myc</i> and N- <i>myc</i> in Small Cell Carcinoma of the Lung. Science, 1986, 233, 461-464.	12.6	238
4	Progressive dysplasia and aneuploidy are hallmarks of mouse skin papillomas: relevance to malignancy Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 2029-2032.	7.1	108
5	Evolution of tumor cytogenetic aberrations and N-myc oncogene amplification in a case of disseminated neuroblastoma. Cancer Genetics and Cytogenetics, 1987, 26, 235-244.	1.0	13
6	Amplification and expression of the N-myc gene in neuroblastoma. European Journal of Pediatrics, 1987, 146, 162-165.	2.7	61
7	myc oncogenes: activation and amplification. Biochimica Et Biophysica Acta: Reviews on Cancer, 1987, 907, 1-32.	7.4	73
8	Cystathionine metabolism in neuroblastoma. Cancer, 1988, 62, 291-298.	4.1	21
9	Association of cytogenetic abnormalities in a neuroblastoma and fragile sites expression. British Journal of Cancer, 1988, 58, 287-291.	6.4	10
10	N-myc amplification at chromosome band 1p32 in neuroblastoma cells as investigated by in situ hybridization. Journal of Cancer Research and Clinical Oncology, 1988, 114, 636-640.	2.5	40
11	Pathologic features of extraosseous Ewing's sarcoma: A report from the intergroup rhabdomyosarcoma study. Human Pathology, 1988, 19, 442-453.	2.0	92
12	Tumorigenicity of ten karyotypically distinct cell types present in the human melanoma cell line MeWo-A. Cancer Genetics and Cytogenetics, 1988, 32, 117-128.	1.0	2
13	Characterization of N-myc amplification units in human neuroblastoma cells Molecular and Cellular Biology, 1988, 8, 522-530.	2.3	48
14	Proto-oncogene activation during chemically induced hepatocarcinogenesis in rodents. Mutation Research - Reviews in Genetic Toxicology, 1989, 220, 1-10.	2.9	18
15	Association of near-diploid DNA content and N-myc amplification in neuroblastomas. Clinical and Experimental Metastasis, 1989, 7, 201-211.	3.3	21
16	Relative tumorigenicities of hybrid cells with and without hsr-bearing chromosomes from a human melanoma cell line. International Journal of Cancer, 1989, 44, 360-366.	5.1	3
17	The variable hematologic expression of the BCR-ABL genomic mutation and its possible determinants. Cancer Genetics and Cytogenetics, 1989, 42, 9-25.	1.0	4
18	Simultaneous existence of double minute chromosomes and a homogeneously staining region in a retinoblastoma cell line (Y79) and amplification of N-myc at HSR. Cancer Genetics and Cytogenetics, 1989, 37, 133-137.	1.0	6

TION RE

ARTICLE IF CITATIONS # Double minutes in two primary adenocarcinomas of the prostate. Cancer Genetics and Cytogenetics, 19 1.0 31 1989, 39, 191-194. Molecular biology and genetics of human neuroblastoma. Cancer Genetics and Cytogenetics, 1989, 41, 1.0 176 153-174. 21 Chromosomal aberrations as markers of oncogene amplification. Human Pathology, 1989, 20, 308-315. 2.0 13 A Contemporary View of Neoplasms in Children: The Pathologist's Perspective. Pediatric Clinics of 1.8 North America, 1989, 36, 113-137. Neuroblastoma -Clinical Applications of Molecular Parameters. Brain Pathology, 1990, 1, 47-54. 23 4.1 34 A comparative analysis of nuclear DNA content and N-myc gene amplification in neuroblastoma. Cancer, 1990, 65, 1360-1366. 4.1 25 Neuroblastoma and Other Childhood Neural Tumors: A Review. Pediatric Pathology, 1990, 10, 175-193. 0.5 29 BREAST CANCER CYTOGENETICS AND BEYOND. ANZ Journal of Surgery, 1990, 60, 327-336. 26 Double minute chromosomes in the leukocytes of a young girl with breast carcinoma. Cancer 27 1.0 19 Genetics and Cytogenetics, 1990, 44, 203-207. Genetic and cellular basis of multistep carcinogenesis., 1990, 46, 469-486. 86 Cytogenetics and molecular biology of small round-cell tumors and related neoplasms. Cancer 29 1.0 40 Genetics and Cytogenetics, 1991, 54, 1-10. Recurrent homogeneously staining regions in 8p1 in breast cancer and lack of amplification of POLB, LHRH, and PLAT genes. Cancer Genetics and Cytogenetics, 1991, 52, 27-35. Cytogenetic analysis of primary neuroblastoma with del(1), del(14), hsr, and dmin chromosomes. $\mathbf{31}$ 1.0 10 Cancer Genetics and Cytogenetics, 1991, 55, 231-234. Chromosome studies of solid tumours.. Journal of Clinical Pathology, 1992, 45, 556-560. Isolation and structural analysis of a 1.2-megabase N-myc amplicon from a human neuroblastoma.. 34 2.351 Molecular and Cellular Biology, 1992, 12, 5563-5570. Dominant and Recessive Molecular Changes in Neuroblastomas. Brain Pathology, 1992, 2, 195-208. Cytogenetic study of breast cancer: Clinicopathologic significance of homogeneously staining 36 2.0 29 regions in 84 patients. Human Pathology, 1992, 23, 542-547. Chromosomal abnormalities in Waldenström's macroglobulinemia. Cancer Genetics and Cytogenetics, 1992, 61, 147-151.

#	Article	IF	CITATIONS
38	Double minute chromatin bodies in carcinoma of the human cervix uteri. Cancer Genetics and Cytogenetics, 1992, 58, 134-140.	1.0	5
39	Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 1992, 358, 80-83.	27.8	1,930
40	N-myc Gene Amplification in Neuroblastoma: A Clinical Approach Using Ultrasound Guided Cutting Needle Biopsies Collected at Diagnosis. Medical and Pediatric Oncology, 1992, 20, 292-300.	1.0	29
41	Neuroblastoma: Effect of genetic factors on prognosis and treatment. Cancer, 1992, 70, 1685-1694.	4.1	134
42	Discerning the function of p53 by examining its molecular interactions. BioEssays, 1993, 15, 703-707.	2.5	29
43	N-myc oncogene and urinary catecholamines in children with neuroblastoma. Medical and Pediatric Oncology, 1993, 21, 499-504.	1.0	11
44	Rhabdomyosarcomas with Primary Presentation in the Skin. Pathology Research and Practice, 1993, 189, 422-427.	2.3	42
45	Molecular Analysis of Gene Amplification in Tumors. Current Protocols in Human Genetics, 1994, 2, Unit 10.5.	3.5	3
46	Cytogenetic abnormalities of small round cell tumours. Medical and Pediatric Oncology, 1994, 23, 124-129.	1.0	30
47	Double minute chromosomes in an invasive adenocarcinoma of the prostate. Cancer Genetics and Cytogenetics, 1994, 72, 157-159.	1.0	10
48	Molecular basis for heterogeneity in human neuroblastomas. European Journal of Cancer, 1995, 31, 505-510.	2.8	156
49	Two-dimensional separations of the genome and proteome of neuroblastoma cells. Electrophoresis, 1996, 17, 1741-1751.	2.4	23
50	REVIEW ARTICLE. THE MOLECULAR PATHOLOGY OF SMALL ROUND-CELL TUMOURS—RELEVANCE TO DIAGNOSIS, PROGNOSIS, AND CLASSIFICATION. Journal of Pathology, 1996, 178, 116-121.	4.5	68
51	Karyotypic Evolution of Cells in Culture: A New Concept. International Review of Cytology, 1997, 178, 1-40.	6.2	28
52	NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology Journal of Clinical Oncology, 1997, 15, 3433-3440.	1.6	60
53	Evaluation of head and neck masses. Indian Journal of Pediatrics, 1997, 64, 771-776.	0.8	1
54	Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavourable outcome. Cancer Letters, 1998, 130, 83-92.	7.2	19
55	CGH-detected DNA sequence copy number amplifications can be confirmed by interphase-FISH: new possiblities for prognostic approaches in oral squamous cell carcinomas International Journal of Molecular Medicine, 1998, 2, 555-60.	4.0	9

#	Article	IF	CITATIONS
56	Posterior Mediastinal Neurogenic Tumors in Infants and Children. Seminars in Pediatric Surgery, 1999, 8, 78-84.	1.1	11
57	Jumping Translocation of Homogeneously Staining Region and Tetraploidy with Double Minutes in Acute Myelomonocytic Leukemia. Cancer Genetics and Cytogenetics, 1999, 109, 40-44.	1.0	20
58	Amplification of C-MYC as the Origin of the Homogeneous Staining Region in Ovarian Carcinoma Detected by Micro-FISH. Cancer Genetics and Cytogenetics, 1999, 114, 136-143.	1.0	17
59	MYCN Gene Amplification. American Journal of Pathology, 1999, 155, 1439-1443.	3.8	29
60	Cytogenetic and molecular findings related to rhabdomyosarcoma. An analysis of seven cases. Cancer Genetics and Cytogenetics, 2003, 144, 125-133.	1.0	14
61	repp86 Expression and Outcome in Patients With Neuroblastoma. Journal of Clinical Oncology, 2003, 21, 1810-1818.	1.6	27
62	Coamplification of DDX1 Correlates With an Improved Survival Probability in Children With MYCN-Amplified Human Neuroblastoma. Journal of Clinical Oncology, 2004, 22, 2681-2690.	1.6	45
63	Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells. Journal of Cellular Biochemistry, 2004, 92, 1282-1295.	2.6	22
64	Loss of one HuD allele on chromosome #1p selects for amplification of the N-myc proto-oncogene in human neuroblastoma cells. Oncogene, 2006, 25, 706-712.	5.9	16
65	Neuroblastoma. Lancet, The, 2007, 369, 2106-2120.	13.7	1,856
67	Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma. Journal of Cancer Research and Clinical Oncology, 2007, 133, 185-192.	2.5	22
68	Slug (SNAI2) Down-Regulation by RNA Interference Facilitates Apoptosis and Inhibits Invasive Growth in Neuroblastoma Preclinical Models. Clinical Cancer Research, 2008, 14, 4622-4630.	7.0	59
69	Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells <i>in vitro</i> and in orthotopic mouse model. International Journal of Cancer, 2009, 125, 2547-2555.	5.1	34
70	Nitric Oxide Control of MYCN Expression and Multi Drug Resistance Genes in Tumours of Neural Origin. Current Pharmaceutical Design, 2010, 16, 431-439.	1.9	13
72	Genetics and Genomics of Neuroblastoma. Cancer Treatment and Research, 2010, 155, 65-84.	0.5	84
73	MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis, 2011, 32, 1005-1012.	2.8	67
74	Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells. Differentiation, 2011, 81, 25-34.	1.9	27
75	A SP1/MIZ1/MYCN Repression Complex Recruits HDAC1 at the <i>TRKA</i> and <i>p75NTR</i> Promoters and Affects Neuroblastoma Malignancy by Inhibiting the Cell Response to NGF. Cancer Research, 2011, 71, 404-412.	0.9	89

#	Article	IF	Citations
76	Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing. Science Translational Medicine, 2012, 4, 162ra154.	12.4	557
77	Prognostic Significance of Promoter DNA Methylation in Patients with Childhood Neuroblastoma. Clinical Cancer Research, 2012, 18, 5690-5700.	7.0	23
78	Genetic Factors Influencing the Risk and Clinical Outcome of Neuroblastoma. , 0, , .		0
79	Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nature Genetics, 2013, 45, 12-17.	21.4	374
80	Phox2B correlates with MYCN and is a prognostic marker for neuroblastoma development. Oncology Letters, 2015, 9, 2507-2514.	1.8	26
81	Detection and Live-Cell Imaging of a Micro-RNA Associated with the Cancer Neuroblastoma. Bioconjugate Chemistry, 2016, 27, 2332-2336.	3.6	2
83	Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E6623-E6631.	7.1	99
84	Thrombospondin-targeting TAX2 peptide impairs tumor growth in preclinical mouse models of childhood neuroblastoma. Pediatric Research, 2017, 81, 480-488.	2.3	9
85	Both serum and tissue Galectinâ€l levels are associated with adverse clinical features in neuroblastoma. Pediatric Blood and Cancer, 2018, 65, e27229.	1.5	10
86	Characterization and Analysis of the Skin Microbiota in Rosacea: A Case–Control Study. American Journal of Clinical Dermatology, 2020, 21, 139-147.	6.7	37
87	Gut, oral and skin microbiome of Indian patrilineal families reveal perceptible association with age. Scientific Reports, 2020, 10, 5685.	3.3	50
88	Pediatric Head and Neck Neoplasms. , 2021, , 364-381.		0
89	Structural changes in the gut microbiota community of the black-necked crane (Grus nigricollis) in the wintering period. Archives of Microbiology, 2021, 203, 6203-6214.	2.2	7
90	Clinical implications of oncogene activation in human neuroblastomas. Cancer, 1986, 58, 541-545.	4.1	41
91	Neuroblastoma: Effect of genetic factors on prognosis and treatment. Cancer, 1992, 70, 1685-1694.	4.1	80
92	Chromosomes in Breast Cancer. , 1987, , 47-65.		2
93	Growth regulation of human neuroblastoma. Cancer Treatment and Research, 1993, 63, 105-128.	0.5	1
94	Patterns and Significance of Genetic Changes in Neuroblastomas. , 1991, , 251-276.		5

<u> </u>			D	
СТ	ΔΤΙ	ON	Report	
	/ / 1 1			

ARTICLE IF CITATIONS Pediatric Head and Neck Malignancies., 2010, , 2835-2849. 4 95 Biology and Genetics of Human Neuroblastomas. The American Journal of Pediatric 1.3 Hematology/oncology, 1997, 19, 93-101. A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the 97 1.8 16 B-MYB/MYCN axis in neuroblastoma. Oncotarget, 2012, 3, 535-545. Cytogenetic and molecular cytogenetic techniques in orthopaedic surgery.. Journal of Bone and Joint 98 Surgery - Series A, 1993, 75, 606-614. A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's 99 2.8 141 sarcoma and neuroblastoma. Health Technology Assessment, 2003, 7, 1-162. Neuroblastoma. Pediatric Annals, 1988, 17, 269-284. 0.8 Music of metagenomicsâ€"a review of its applications, analysis pipeline, and associated tools. 101 3.5 3 Functional and Integrative Genomics, 2022, 22, 3-26. Pediatric Cancer Mechanisms of Cancer Growth and Progression., 2010, , 129-147. Cytogenetics and Molecular Genetics of Cell Transformation in Vitro by Mutagens/Carcinogens. 103 0.2 0 Advances in Mutagenesis Research, 1990, , 275-302. 104 Characterization of the Stage of Progression in Hepatocarcinogenesis in the Rat., 1991, 57, 3-18. Isolation and Structural Analysis of a 1.2-Megabase N-<i>myc</i> 105 2.324 Neuroblastoma. Molecular and Cellular Biology, 1992, 12, 5563-5570. Characterization of N-myc amplification units in human neuroblastoma cells. Molecular and Cellular 2.3 Biology, 1988, 8, 522-530. The genetics of vascular tumours: an update. Histopathology, 2022, 80, 19-32. 108 2.9 10 Human microbiota research in Africa: a systematic review reveals gaps and priorities for future 109 11.1 research. Microbiome, 2021, 9, 241. Pediatric Head and Neck Malignancies., 2015, , 272-292.e2. 111 0 Correlation between ARID1B gene mutation (p.A460, p.V215G) and prognosis of highâ€risk refractory neuroblastoma. Cell Biology International, 2023, 47, 1222-1228. The Nâ€<i>myc</i> Protoâ€oncogene: Developmental Expression and <i>in vivo</i> Siteâ€Directed 113 4.1 23 Mutagenesis. Brain Pathology, 1991, 2, 71-83.